NCT04693468View on ClinicalTrials.gov

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

PHASE1RecruitingINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid Neoplasm
Interventions
DRUG

Axitinib

Given PO

DRUG

Crizotinib

Given PO

DRUG

Palbociclib Isethionate

Given PO

DRUG

Talazoparib Tosylate

Given PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT04693468 - Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial | Biotech Hunter | Biotech Hunter